Alkermes Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Alkermes zullen naar verwachting dalen met respectievelijk 0.7% en 7% per jaar. De winst per aandeel zal naar verwachting afnemen met 9.4% per jaar. Het rendement op het eigen vermogen zal naar verwachting 15.9% in 3 jaar.

Belangrijke informatie

-7.0%

Groei van de winst

-9.4%

Groei van de winst per aandeel

Biotechs winstgroei	27.3%
Inkomstengroei	-0.7%
Toekomstig rendement op eigen vermogen	15.9%
Dekking van analisten	Good
Laatst bijgewerkt	04 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NasdaqGS:ALKS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1,485	251	468	413	11
12/31/2025	1,424	206	287	329	14
12/31/2024	1,507	328	334	399	14
9/30/2024	1,505	387	315	356	N/A
6/30/2024	1,508	386	327	374	N/A
3/31/2024	1,726	570	394	444	N/A
12/31/2023	1,663	519	353	401	N/A
9/30/2023	1,591	455	254	295	N/A
6/30/2023	1,462	300	159	196	N/A
3/31/2023	1,121	-9	-59	-22	N/A
12/31/2022	1,112	-33	-17	21	N/A
9/30/2022	1,132	-129	14	51	N/A
6/30/2022	1,173	-94	102	133	N/A
3/31/2022	1,201	-62	140	169	N/A
12/31/2021	1,174	76	73	102	N/A
9/30/2021	1,129	-92	112	138	N/A
6/30/2021	1,100	-63	88	115	N/A
3/31/2021	1,044	-95	48	78	N/A
12/31/2020	1,039	-111	41	83	N/A
9/30/2020	1,171	-74	-11	58	N/A
6/30/2020	1,162	-126	-53	28	N/A
3/31/2020	1,194	-139	-78	10	N/A
12/31/2019	1,171	-197	-19	72	N/A
9/30/2019	1,074	-201	14	91	N/A
6/30/2019	1,067	-183	19	93	N/A
3/31/2019	1,092	-173	74	148	N/A
12/31/2018	1,094	-139	30	99	N/A
9/30/2018	1,054	-139	5	75	N/A
6/30/2018	1,023	-141	N/A	61	N/A
3/31/2018	937	-152	N/A	6	N/A
12/31/2017	903	-158	N/A	19	N/A
9/30/2017	842	-169	N/A	-9	N/A
6/30/2017	804	-196	N/A	-14	N/A
3/31/2017	781	-200	N/A	-20	N/A
12/31/2016	746	-208	N/A	-64	N/A
9/30/2016	695	-257	N/A	-69	N/A
6/30/2016	668	-275	N/A	-113	N/A
3/31/2016	624	-274	N/A	-100	N/A
12/31/2015	628	-227	N/A	-40	N/A
9/30/2015	640	-127	N/A	-29	N/A
6/30/2015	648	-86	N/A	-7	N/A
3/31/2015	650	-36	N/A	17	N/A
12/31/2014	619	-30	N/A	11	N/A
9/30/2014	598	-42	N/A	36	N/A
6/30/2014	578	-10	N/A	85	N/A
3/31/2014	563	-7	N/A	89	N/A
12/31/2013	596	21	N/A	148	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De winst van ALKS zal naar verwachting de komende 3 jaar dalen ( -7% per jaar).

Winst versus markt: De winst van ALKS zal naar verwachting de komende 3 jaar dalen ( -7% per jaar).

Hoge groeiwinsten: De winst van ALKS zal naar verwachting de komende 3 jaar dalen.

Omzet versus markt: De omzet van ALKS zal naar verwachting de komende 3 jaar dalen ( -0.7% per jaar).

Hoge groei-inkomsten: De omzet van ALKS zal naar verwachting de komende 3 jaar dalen ( -0.7% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ALKS zal naar verwachting over 3 jaar laag zijn ( 15.9 %).

Alkermes Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.3% to US$35.50

Consensus EPS estimates increase by 52%

Alkermes plc Revises Earnings Guidance for the Fiscal Year 2023

Price target decreased by 7.5% to US$33.10

Forecast breakeven date moved forward to 2023

Forecast breakeven date moved forward to 2023

Recent updates

Third quarter 2024 earnings: EPS misses analyst expectations

Alkermes plc to Report Q3, 2024 Results on Oct 24, 2024

Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement

New major risk - Revenue and earnings growth

Is Alkermes (NASDAQ:ALKS) A Risky Investment?

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

Alkermes: Fairly Valued After Post-Earnings Bump

Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

The Bottom Fishing Club: Alkermes Has Great Value And Safety

Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Alkermes plc to Report Q1, 2024 Results on May 01, 2024

Alkermes plc, Annual General Meeting, May 31, 2024

Price target increased by 7.3% to US$35.50

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

New minor risk - Shareholder dilution

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Consensus EPS estimates increase by 52%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alkermes plc (NasdaqGS:ALKS) announces an Equity Buyback for $400 million worth of its shares.

Alkermes plc to Report Q4, 2023 Results on Feb 15, 2024

Alkermes plc Announces Executive Changes

Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet

Alkermes plc Announces Changes to its Board

Alkermes plc Revises Earnings Guidance for the Fiscal Year 2023

Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Price target decreased by 7.5% to US$33.10

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkermes plc to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkermes plc to Report Q2, 2023 Results on Jul 26, 2023

Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?

Forecast breakeven date moved forward to 2023

Sarissa Issues Presentation for Alkermes Shareholders

Sarissa Capital Management Issues a Presentation to Shareholder of Alkermes plc

Sarissa Capital Management Issues a Presentation to Shareholder of Alkermes plc

Sarissa Capital Management Issues a Presentation to Shareholder of Alkermes plc

Forecast breakeven date moved forward to 2023

Sarissa Capital Issues a Letter to Shareholders of Alkermes

There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding

Consensus EPS estimates have been upgraded.

Alkermes plc, Annual General Meeting, Jun 29, 2023

Consensus estimates of losses per share improve by 76%

Lead Independent Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Chairman & CEO exercised options and sold US$399k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Alkermes plc Provides Earnings Guidance for the Year 2023

Alkermes plc to Report Q4, 2022 Results on Feb 16, 2023

Sarissa Capital Engages with the Alkermes plc

High number of new directors

Alkermes plc Awards Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

Alkermes plc Revises Earnings Guidance for 2022

Alkermes upgraded to neutral at BofA on improved risk/reward outlook

Alkermes holder Sarissa Capital says it may look to increase its stake

Alkermes: Nothing Stands Out As Interesting

Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Alkermes initiated at neutral at Piper Sandler as company in transition

Consensus estimates of losses per share improve by 15%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alkermes plc Revises Earnings Guidance for the Full Year 2022